The tumour-suppressor p53 is not required for pancreatic β cell death during diabetes and upon irradiation

Journal of Physiology

Volumn 586, Issue 2, 2008, Pages 407-417

  Nam, Shin Yuen ^a   Lee, Ming Kei ^a   Sabapathy, Kanaga ^a,b  

^a DIVISION OF MEDICAL ONCOLOGY   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; INSULIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; PROTEIN ANTIBODY; PROTEIN P53; PROTEIN P53 ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL COUNT; CELL DEATH; CELL STRUCTURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE COURSE; FEMALE; GAMMA IRRADIATION; GENE OVEREXPRESSION; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; IMMUNOREACTIVITY; INSULIN BLOOD LEVEL; MALE; MOUSE; NICK END LABELING; NONHUMAN; PANCREAS ISLET BETA CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSGENIC MOUSE; WILD TYPE; DIABETOGENESIS; TUNEL ASSAY;

ANIMALS; APOPTOSIS; DIABETES MELLITUS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FEMALE; GENE EXPRESSION REGULATION; H-2 ANTIGENS; HISTOCOMPATIBILITY ANTIGENS CLASS I; INSULIN-SECRETING CELLS; MALE; MICE; MICE, TRANSGENIC; PHENOTYPE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 38149028453     PISSN: 00223751     EISSN: 14697793     Source Type: Journal    
DOI: 10.1113/jphysiol.2007.142612     Document Type: Article

References (40)

1. Allen TJ, Cooper ME & Lan HY (2004). Use of genetic mouse models in the study of diabetic nephropathy. Curr Diab Rep 4, 435-440.
2. Allison J, Campbell IL, Morahan G, Mandel TE & Harrison LC (1988). Diabetes in transgenic mice resulting from over-expression of class I histocompatibility molecules in pancreatic β cells. Nature 333, 529-533.
3. 2-microglobulin in transgenic mouse islet β cells results in defective insulin secretion. Proc Natl Acad Sci U S A 88, 2070-2074.
4. Bargonetti J & Manfredi JJ (2002). Multiple roles of the tumor suppressor p53. Curr Opin Oncol 14, 86-91.
5. Bouvard V, Zaitchouk T, Vacher M, Duthu A, Canivet M, Choisy-Rossi C, Nieruchalski M & May E (2000). Tissue and cell-specific expression of the p53 target genes: Bax, fas, mdm2 and waf1/p21, before and following ionizing irradiation in mice. Oncogene 19, 649-660.
6. Braithwaite AW & Prives CL (2006). p53: More research and more questions. Cell Death Differ 13, 887-880.
7. Buschard K (1996). Diabetic animal models. APMIS 104, 609-614.
8. Chakravarthy MV & Semenleovoch CF (2007). The ABCs of B cell dysfunction in type-2 diabetes. Nat Med 13, 340-347.
9. Cnop M, Welsh N, Jonas JC, Jörns A, Lenzen S & Eizirik DL (2005). Mechanisms of pancreatic β-cell death in type-1 and type-2 diabetes: Many differences, few similarities. Diabetes 54 (Suppl. 2), S97-S107.
10. Donath MY, Ehses JA, Maedler K, Schumman DM, Ellingsgaard H, Eppler E & Reinecke M (2005). Mechanisms of β-cell death in type-2 diabetes. Diabetes 54 (Suppl. 2), S108-S113.
11. Faideau B, Larger E, Lepault F, Carel JC & Boitard C (2002). Role of β-cells in type-1 diabetes pathogenesis. Diabetes 54, S87-S96.
12. Fei P, Bernhard EJ & El-Deiry WS (2002). Tissue-specific induction of p53 targets in vivo. Cancer Res 62, 7316-7327.
13. Hassa PO & Hottiger MO (2002). The functional role of poly (ADP-ribose) polymerase 1 as novel coactivator of NF-κB in inflammatory disorders. Cell Mol Life Sci 59, 1534-1553.
14. Jacks T, Remington L, Williams BO, Schmitt EM, Halachmi S, Bronson RT & Weinberg RA (1994). Tumour spectrum analysis in p53-mutant mice. Curr Biol 4, 1-7.
15. Jörns A, Tiedge M, Ziv E, Shafrir E & Lenzen S (2002). Gradual loss of pancreatic β-cell insulin, glucokinase and GLUT2 glucose transporter immunoreactivities during the time course of nutritionally induced type-2 diabetes in Psammomys obesus (sand rat). Virchows Arch 440, 63-69.
16. Lamhamedi-Cherradi SE, Zheng S, Hilliard BA, Xu L, Sun J, Alsheadat S, Liou HC & Chen YH (2003). Transcriptional regulation of type I diabetes by NF-κ. J Immunol 171, 4886-4892.
17. Laybutt DR, Preston AM, Akerfeldt MC, Kench JG, Busch AK, Biankin AV & Biden TJ (2007). Endoplasmic reticulum stress contributes to β cell apoptosis in type-2 diabetes. Diabetologia 50, 752-763.
18. Liadia N, Murakami K, Eweida M, Elford AR, Sheu L, Gaisano HY, Hakem R, Ohashi PR & Woo M (2005). Caspase-3-dependent β-cell apoptosis in the initiation of autoimmune diabetes mellitus. Mol Cell Biol 25, 3620-3629.
19. Mandel TE, Allison J, Cambell IL, Koulmanda M, Malcolm L, Cutri A & Miller JF (1991). Inherent β-cell dysfunction induced by transgenic expression of allogeneic major histocompatibility complex class I antigen in islet cells. Autoimmunity 9, 47-53.
20. Midgley CA, Owens B, Briscoe C, Thomas DB, Lane CP & Hall PA (1995). Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. J Cell Sci 108, 1843-1848.
21. Movassat J, Saulnier C & Portha B (1995). β-cell mass depletion precedes the onset of hyperglycaemia in the GK rat, a genetic model of non-insulin-dependent diabetes mellitus. Diabete Metab 21, 365-370.
22. Naik P, Karrim J & Hanahan D (1996). The rise and fall of apoptosis during multistage tumorigenesis: Down-modulation contributes to tumor progression from angiogenic progenitors. Genes Dev 10, 2105-2116.
23. Oren M (2003). Decision making by p53: Life, death and cancer. Cell Death Differ 10, 431-442.
24. Oyadomari S, Araki E & Mori M (2002). Endoplasmic reticulum stress-mediated apoptosis in pancreatic β-cells. Apoptosis 7, 335-345.
25. Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, Tuncman G, Gorgun C, Glimcher LH & Hotamisligil GS (2004). Endoplasmic reticulum stress links obesity, insulin action, and type-2 diabetes. Science 306, 451-461.
26. Pani L, Horal M & Loeken MR (2006). Rescue of neural tube defects in Pax-3-deficient embryos by p53 loss of function: Implications for Pax-3-dependent development and tumorigenesis. Genes Dev 16, 676-680.
27. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P & Olivier M (2007). TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 26, 2157-2165.
28. Ramel S, Sanchez CA, Schimke MK, Neshat K, Cross SM, Raskind WH & Reid BJ (1995). Inactivation of p53 and the development of tetraploidy in the elastase-SV40 T antigen transgenic mouse pancreas. Pancreas 11, 213-222.
29. Rhodes CJ (2005). Type 2 diabetes -a matter of β-cell life and death?Science 21, 380-384.
30. Riggs AC, Bernal-Mizrachi E, Ohsugi M, Wasson J, Fatrai S, Welling C, Murray J, Schmidt RE, Herrera PL & Permutt MA (2005). Mice conditionally lacking the Wolfram gene in pancreatic islet β cells exhibit diabetes as a result of enhanced endoplasmic reticulum stress and apoptosis. Diabetologia 48, 2313-2321.
31. Sah VP, Attardi LD, Mulligan GJ, Williams BO, Bronson RT & Jacks T (1995). A subset of p53-deficient embryos exhibit exencephaly. Nat Genet 10, 175-180.
32. Shafrir E (2001). Albert Renold memorial lecture: Molecular background of nutritionally induced insulin resistance leading to type-2 diabetes -from animal models to humans. Int J Exp Diabetes Res 2, 299-319.
33. Sigal A & Rotter V (2000). Oncogenic mutations of the p53 tumor suppressor: The demons of the guardian of the genome. Cancer Res 60, 6788-6793.
34. Slee EA, O'Connor DJ & Lu X (2004). To die or not to die: How does p53 decide?Oncogene 23, 2809-2818.
35. Sphyris N & Harrison DJ (2005). p53 deficiency exacerbates pleiotropic mitotic defects, changes in nuclearity and polyploidy in transdifferentiating pancreatic acinar cells. Oncogene 24, 2184-2194.
36. Trovato M, D'Armiento M, Lavra L, Ulivieri A, Dominia R, Vitarelli E, Groisso M, Vecchione R, Barresi G & Sciacchitano S (2007). Expression of p53/hgf/c-met/STAT3 signal in fetuses with neural tube defects. Vichows Arch 450, 203-210.
37. Uchida T, Nakamura T, Hashimoto N, Matsuda T, Kotani K, Sakaue H, Kido Y, Hayashi Y, Nakayama KL, White MF & Kasuga M (2005). Deletion of Cdkn1b ameliorates hyperglycemia by maintaining compensatory hyperinsulinemia in diabetic mice. Nat Med 11, 175-182.
38. Umpierrez GE (2006). Ketosis-prone type-2 diabetes: Time to revise the classification of diabetes. Diabetes Care 29, 2755-2757.
39. Zhang B, Lu Y, Campbell-Thompson M, Spencer T, Wasserfall C, Atkinson M & Song S (2007). α1-Antitrypsin protects β-cells from apoptosis. Diabetes 56, 1316-1323.
40. Zheng SJ, Lamhamedi-Cherradi SE, Wang P, Xu L & Chen YH (2005). Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 54, 1423-1428.